공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

시장 스포트라이트 : 자궁경부암

Market Spotlight: Cervical Cancer

리서치사 Datamonitor Healthcare
발행일 2021년 03월 상품 코드 573573
페이지 정보 영문 48 Pages
가격
US $ 1,318 ₩ 1,486,000 PDF (Single User License)


시장 스포트라이트 : 자궁경부암 Market Spotlight: Cervical Cancer
발행일 : 2021년 03월 페이지 정보 : 영문 48 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

자궁경부암 치료제 시장을 분석했으며, 질환 개요 및 환자수 추이·전망, 현단계의 주요 치료법 및 임상시험·인가 상황, 자궁경부암 치료제 시장의 동향 전망(향후 10년간), 자본거래 동향, 현재 개발중인 임상시험의 진행 상황 등을 조사하여 전해드립니다.

1. 분석 포인트

2. 질환 배경

3. 치료법

  • 수술
  • 방사선 치료
  • 화학요법
  • 표적치료

4. 역학

5. 파이프라인상 의약품

6. 출시 의약품

  • 각국에서의 인증 상황

7. 향후 주요 동향

8. 라이선스 계약·자산 인수 거래(총 2건)

9. 모특허

10. 매출 기회

11. 임상시험 상황

12. 관련 분석

  • 처방약 정보

13. 부록

14. 도표

KSA 17.11.20

This Market Spotlight report covers the Cervical Cancer market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, licensing and acquisition deals, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

Datamonitor Healthcare estimates that in 2017, there were 564,900 incident cases of cervical cancer in females worldwide, and expects that number to increase to 618,400 incident cases by 2026.

Approved drugs for cervical cancer target vascular endothelial growth factor, topoisomerase I, programmed death-1 receptor (PD-1)/programmed death ligands (PD-L1 and PD-L2), the immune system, and reactive oxygen species/free radicals. The majority of these therapies are administered via the intravenous route.

The majority of the industry-sponsored drugs in active clinical development for cervical cancer are in Phase II, with three drugs in the NDA/BLA stage.

Therapies in development for cervical cancer focus on a wide variety of targets. The majority of the pipeline drugs are administered via the intravenous route, with the remainder being oral, subcutaneous, intramuscular, intravesical, and intranasal formulations.

High-impact upcoming events for drugs in the cervical cancer space comprise topline Phase III trial results for Libtayo and Imfinzi, and expected PDUFA dates for biosimilar bevacizumab (Mylan/Biocon) and tisotumab vedotin.

The overall likelihood of approval of a Phase I solid tumors asset is 5.4%, and the average probability a drug advances from Phase III is 43%. Drugs, on average, take 9.7 years from Phase I to approval, compared to 9.6 years in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for cervical cancer have been in the early and mid-phases of development, with 94% of trials in Phase I-II, and only 6% in Phase III-IV.

The US has a substantial lead in the number of cervical cancer clinical trials globally. The UK leads the major European markets, while China has the top spot in Asia.

Roche has the highest number of completed clinical trials for cervical cancer, with 16 trials.

AstraZeneca leads industry sponsors with the highest overall number of clinical trials for cervical cancer.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Surgery
  • Radiotherapy
  • Chemotherapy
  • Targeted therapy
  • Immunotherapy

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Tisotumab Vedotin for Cervical Cancer (September 21, 2020)
  • Balstilimab for Cervical Cancer (September 18, 2020)
  • Tisotumab Vedotin for Cervical Cancer (June 29, 2020)
  • GX-188E for Cervical Cancer (April 27, 2020)
  • Multiple Drugs for Cervical Cancer (February 20, 2020)
  • HLX10 for Cervical Cancer (September 12, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Agenus Kicks Off Rolling BLA For Balstilimab
  • Samsung Bioepis Receives EU Bevacizumab Approval
  • Biosimilar Avastin Is Launched In India
  • Mylan Reveals FDA Goal Date For Bevacizumab

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Biomm Backs Bio-Thera's Brazilian Bevacizumab
  • Betta Gains China-Plus Rights To Two Agenus Oncology Drugs

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of cervical cancer, 2017-26
  • Figure 2: Overview of pipeline drugs for cervical cancer in the US
  • Figure 3: Pipeline drugs for cervical cancer, by company
  • Figure 4: Pipeline drugs for cervical cancer, by drug type
  • Figure 5: Pipeline drugs for cervical cancer, by classification
  • Figure 6: Tisotumab Vedotin for Cervical Cancer (September 21, 2020): Phase II - innovaTV 204
  • Figure 7: Balstilimab for Cervical Cancer (September 18, 2020): Phase II - RaPiDS (+/- AGEN1884, 2nd Line)
  • Figure 8: Tisotumab Vedotin for Cervical Cancer (June 29, 2020): Phase II - innovaTV 204
  • Figure 9: GX-188E for Cervical Cancer (April 27, 2020): Phase Ib/IIa - w/Pembrolizumab (Korea)
  • Figure 10: Multiple Drugs for Cervical Cancer (February 20, 2020): Phase II - RaPiDS
  • Figure 11: Key upcoming events in cervical cancer
  • Figure 12: Probability of success in the solid tumors pipeline
  • Figure 13: Clinical trials in cervical cancer
  • Figure 14: Top 10 drugs for clinical trials in cervical cancer
  • Figure 15: Top 10 companies for clinical trials in cervical cancer
  • Figure 16: Trial locations in cervical cancer
  • Figure 17: Cervical cancer trials status
  • Figure 18: Cervical cancer trials sponsors, by phase

LIST OF TABLES

  • Table 1: Incident cases of cervical cancer, 2017-26
  • Table 2: Marketed drugs for cervical cancer
  • Table 3: Pipeline drugs for cervical cancer in the US
  • Table 4: Tisotumab Vedotin for Cervical Cancer (September 21, 2020)
  • Table 5: Balstilimab for Cervical Cancer (September 18, 2020)
  • Table 6: Tisotumab Vedotin for Cervical Cancer (June 29, 2020)
  • Table 7: GX-188E for Cervical Cancer (April 27, 2020)
  • Table 8: Multiple Drugs for Cervical Cancer (February 20, 2020)
  • Table 9: HLX10 for Cervical Cancer (September 12, 2019)
  • Table 10: Historical global sales, by drug ($m), 2015-19
  • Table 11: Forecasted global sales, by drug ($m), 2021-25
Back to Top
전화 문의
F A Q